Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC)
NCT ID: NCT01574430
Last Updated: 2016-08-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
131 participants
INTERVENTIONAL
2010-12-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Different Doses of vPDT in the Treatment of cCSC
NCT05390619
Effects of OCTA-guided PDT in Acute CSC
NCT03497000
The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
NCT01630863
Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy
NCT01019668
Two Patterns of Micropulse Laser in the Treatment of Chronic Central Serous Chorioretinopathy
NCT05687422
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
50% dose PDT
patients in this group was given 50% verteporfin dose PDT
PDT
30% or 50% verteporfin dose PDT was given to patients with CSC
30% dose PDT
patients in this group was given 30% verteporfin dose PDT
PDT
30% or 50% verteporfin dose PDT was given to patients with CSC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PDT
30% or 50% verteporfin dose PDT was given to patients with CSC
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients signed the ICF
* patients with course of CSC less than 6 months
* patients did not undertake any treatment for CSC
Exclusion Criteria
* patients allergic to verteporfin
* pregnant or nursing women
* poor patients compliance
* sever liver dysfunction
* dioptric media opacities which make it difficult to exam fundus
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mingwei Zhao
Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mingwei Zhao, M.D
Role: STUDY_DIRECTOR
Peking University People's Hospital
Youxin Chen, M.D
Role: PRINCIPAL_INVESTIGATOR
Peking Union Medical College
Feng Zhang, M.D
Role: PRINCIPAL_INVESTIGATOR
Beijing Tongren Hospital of Capital Medical University
Hong Dai, M.D
Role: PRINCIPAL_INVESTIGATOR
Beijing Hospital
Xiaoxin Li, M.D
Role: STUDY_CHAIR
Peking University People's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
People's Hospital of Peking University
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lange CA, Qureshi R, Pauleikhoff L. Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev. 2025 Jun 16;6(6):CD011841. doi: 10.1002/14651858.CD011841.pub3.
Zhao M, Zhang F, Chen Y, Dai H, Qu J, Dong C, Kang X, Liu Y, Yang L, Li Y, Zhou P, Pan CT, Zhang L, Liu P, Zhou H, Jiao X, Xiong Y, Tian R, Lu Y, Yu X, Li X. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial. JAMA Ophthalmol. 2015 Mar;133(3):333-40. doi: 10.1001/jamaophthalmol.2014.5312.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PDTCSC-CHINA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.